Syneron Medical (ELOS) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
OEM Customer Loss Drives Revenue Miss on Syneron Medical Ltd (ELOS); Leerink Partners Cuts Price Target to $9.40
November 12, 2015 6:52 AM ESTLeerink Partners maintained an Outperform rating on Syneron Medical (NASDAQ: ELOS), and cut the price target to $9.40 (from $16.00), following the company's 3Q earnings report. Revenues of $62.1M missed estimates by ~$4M due mainly to an OEM customer loss & weakness in the EMEA region.
Analyst Richard Newitter commented, "As evidenced by... More
